Brief: Algernon Scales Up Manufacturing Of Np-120 (Ifenprodil) To Prepare For Coronavirus And Acute Lung Injury U.S. Clinical Trials
09/03/2020 12:48
March 9 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON SCALES UP MANUFACTURING OF NP-120 (IFENPRODIL) TO
PREPARE FOR CORONAVIRUS AND ACUTE LUNG INJURY US CLINICAL TRIALS
* ALGERNON PHARMACEUTICALS - MADE DECISION TO BEGIN
PRODUCTION OF
NP-120 (IFENPRODIL) WITH A NEW INJECTABLE AND LONG ACTING ORAL
RELEASE FORMULATION
Source text for Eikon: ID:nGNX3TJfZ7
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement